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ABSTRACT: In 2011, we conducted a field trial in rural West Virginia, USA to evaluate the safety
and immunogenicity of a live, recombinant human adenovirus (AdRG1.3) rabies virus glycoprotein
vaccine (Ontario Rabies Vaccine Bait; ONRAB) in wild raccoons (Procyon lotor) and striped
skunks (Mephitis mephitis). We selected ONRAB for evaluation because of its effectiveness in
raccoon rabies management in Ontario and Quebec, Canada, and significantly higher antibody
prevalence rates in raccoons compared with a recombinant vaccinia-rabies glycoprotein
(V-RG) vaccine, Raboral V-RGH, in US–Canada border studies. Raccoon rabies was enzootic
and oral rabies vaccination (ORV) had never been used in the study area. We distributed 79,027
ONRAB baits at 75 baits/km2 mostly by fixed-wing aircraft along parallel flight lines at 750-m
intervals. Antibody prevalence was significantly higher at 49.2% (n5262) in raccoons after
ONRAB was distributed than the 9.6% (n5395) before ORV. This was the highest antibody
prevalence observed in raccoons by US Department of Agriculture Wildlife Services for areas with
similar management histories evaluated before and after an initial ORV campaign at 75 baits/km2
with Raboral V-RG. Tetracycline biomarker (TTCC) was significantly higher among antibody-
positive raccoons after ONRAB baiting and was similar among raccoons before ORV had been
conducted, an indication of vaccine-induced rabies virus–neutralizing antibody production
following consumption of bait containing TTCC. Skunk sample size was inadequate to assess
ONRAB effects. Safety and immunogenicity results supported replication of this field trial and led
to a recommendation for expanded field trials in 2012 to evaluate safety and immunogenicity of
ground-distributed ONRAB at 150 baits/km2 in residential and commercial habitats in Ohio, USA
and aerially distributed ONRAB at 75 baits/km2 in rural habitats along US–Quebec border.
Key words: AdRG1.3, ONRAB, oral rabies vaccination, rabies, raccoon, skunk.
INTRODUCTION
Coordinated oral rabies vaccination
(ORV) with a recombinant vaccinia-rabies
glycoprotein (V-RG) vaccine Raboral V-
RGH (Merial, A SANOFI Company,
Athens, Georgia, USA) has resulted in
canine rabies elimination in coyotes (Ca-
nis latrans; Fearneyhough et al. 1998;
Sidwa et al. 2005), and the US was
declared canine rabies free in 2008
(Velasco-Villa et al. 2008). Oral rabies
vaccination has been successfully applied
in gray foxes (Urocyon cinereoargenteus)
in Texas, USA (Sidwa et al. 2005), with no
reported cases since May 2009 (Blanton et
al. 2011), until a reported case in a cow in
May 2013 (E. Oertli pers. comm.). ORV
has prevented appreciable spread of
raccoon (Procyon lotor) rabies to the west
in the US (Slate et al. 2009).
Although these accomplishments are
important, the inability to eliminate rac-
coon rabies from high-risk corridors
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prompted the evaluation of vaccine baits
potentially capable of producing popula-
tion immunity levels necessary to achieve
this goal (USDA 2010b). A live, recombi-
nant human adenovirus–rabies glycopro-
tein vaccine (AdRG1.3; Charlton et al.
1992), designated Ontario Rabies Vaccine
Bait (ONRAB; Artemis Technologies,
Guelph, Ontario, Canada; Fig. 1), was
selected on the basis of 1) its use along
the US–Canada border without untoward
events and success in reducing and
eliminating raccoon rabies (Rosatte
et al. 2009b; Mainguy et al. 2012); 2) lack
of timely access to other vaccines for field
testing; 3) absence of reported rabid
striped skunks (Mephitis mephitis) infect-
ed with the raccoon rabies virus variant
in Ontario since 2004 and Quebec since
2009 (D. Donovan and J. Mainguy pers.
comm.), suggesting dependence on virus
spillover from the raccoon reservoir; 4)
published and unpublished ONRAB data
from Canada (USDA 2008a; Rosatte et al.
2009a; Rees et al. 2011); 5) results of border
studies comparing ONRAB and Raboral V-
RG under similar environmental and rabies
management conditions (Fehlner-Gardiner
et al. 2012; Mainguy et al. 2013); and 6)
effectiveness in controlling rabies in resid-
ual foci in skunks through high bait
densities (300 baits/km2) and narrow flight
lines (250 m; Rosatte et al. 2011). We
summarize key safety and immunogenicity
findings of this ONRAB trial in raccoons
and skunks, the first study of this type in the
US in.20 yr (Hanlon et al. 1998; Roscoe et
al. 1998), and discuss management impli-
cations and recommendations.
MATERIALS AND METHODS
Study area
The 1,460 km2 field trial site in West
Virginia, USA (37u449N, 80u359W) consisted
of hardwood, mixed coniferous-hardwood, and
evergreen forests (61%); livestock agriculture
characterized by pasture/hay (23%); small
towns (2%); and other habitats (14%; USDA
2011a; USGS 2014). Habitats were character-
ized by Strausbaugh and Core (1978) and
Fleming et al. (2006). No ORV had been
conducted in this study area, which was
enzootic for raccoon rabies (Fig. 2).
Field trial design
The design included four 127-km2 sampling
cells separated by a 5-km buffer (Fig. 3). An 11-
km buffer was established from the western edge
of the ONRAB sampling cells to the Raboral
V-RG zone baited at 75 baits/km2 since 2001
(USDA 2005) to reduce the chance of confound-
ed serologic results. A 5-km buffer was estab-
lished from the sampling cell perimeters within
the ONRAB baited area to reduce potential
dilution effect from sampling raccoons with
home ranges that extended into unbaited areas.
Oral rabies vaccine bait
The virus vector is well characterized
(Graham and Prevec 1992). The Ultralite bait
and live AdRG1.3, constituting ONRAB, have
been described (Rosatte et al. 2009b). The
matrix contained 100 mg of tetracycline
hydrochloride (TTCC) biomarker (Rosatte et
al. 2009b). There were 77,447 ONRAB baits
aerially distributed along parallel flight lines at
750-m intervals at 75 baits/km2; 1,580 ONRAB
baits were distributed at the same bait density
by ground means near and within towns where
aerial baiting was deemed unsafe. Baits had a
warning label with a toll-free number (Fig. 1)
to facilitate communication of potential bait
and vaccine exposures to the West Virginia
Department of Health and Human Resources
(WVDHHR).
Animal capture, handling, and sampling
Biologic and serologic sampling: Animal sam-
pling included live (cage) trapping (Tomahawk
FIGURE 1. Ontario Rabies Vaccine Bait (ONRAB)
distributed in the oral rabies vaccine field trial in West
Virginia, USA, 2011. (Photo: Wildlife Services’ Rabies
Management Program Photo Library)
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model 608, Tomahawk Live Trap LLC, Hazel-
hurst, Wisconsin, USA) and release of target
species apparently not rabid based on behavior
and gross examination. Rabies suspects were
tested using a direct rapid immunohistochem-
istry test (Lembo et al. 2006), with rabies
confirmation and virus variant typing by the
Centers for Disease Control and Prevention
(CDC). Nontarget species were released or
collected for future histopathologic analysis. We
set 150 live traps within 800 m of 25 preselected
random points within sampling cells (Fig. 3).
Traps were checked for 10 consecutive days.
The same random points were used pre- and
post-ORV sampling, 2–26 August 2011 and 21–
31 October 2011, respectively.
Captured rabies reservoir species were
sedated using an intramuscular injection of a
5:1 ketamine:xylazine (Kreeger 1999), to
collect blood for rabies virus–neutralizing
antibody (RVNA) determination, and first
premolar tooth samples for age and biomarker
analysis. Sex, reproductive status, and general
condition were recorded. Serum samples were
collected from blood centrifuged the day of
capture and stored in labeled cryovials at
225 C to 270 C before shipment for analysis.
Raccoons and skunks were released at their
capture site after recovery from sedation.
Oral swab sampling: Oral swab samples were
collected 1–6 days after ONRAB distribution
through live trapping in the three spaces
between the four sampling cells (Fig. 3). This
scheme was used to reduce the chance of trap
shyness among raccoons and skunks sampled
post-ORV, which began 5 wk after bait
distribution, approximating the minimum time
for serologic response from ONRAB con-
sumption (Brown et al. 2012).
RVNA determination
Labeled cryovials containing serum were
shipped to CDC frozen on dry ice after pre-
FIGURE 2. Raccoon (Procyon lotor) rabies virus variant (RRV) case history in West Virginia (WV), USA,
2007–11 within an 83-km radius of the center of the 2011 Ontario Rabies Vaccine Bait (ONRAB) oral rabies
vaccination (ORV) zone (gray shading). Each dot represents a confirmed case of RRV in an animal, and the
hatched area represents the 2011 vaccinia-rabies glycoprotein (V-RG) ORV zone.
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and post-ORV sampling. The rapid fluorescent
focus inhibition test (Smith et al. 1973; CDC
2011) was used to determine RVNA titer.
Samples with international units (IUs) $0.06
were considered RVNA positive.
AdRG1.3-neutralizing antibody determination
Frozen serum was shipped in labeled
cryovials on dry ice to the Animal Health
Diagnostic Center, Cornell University (Ithaca,
New York, USA), to determine AdRG1.3
virus–neutralizing antibody (VNA) pre- and
post-ORV sampling. The adenovirus virus
neutralization assay followed standard proce-
dures. Twofold serum dilutions (50 mL) in
duplicate were mixed with 100–300, 50%
tissue culture infectious doses of Ad-5 (VR-5,
American Type Culture Collection [ATCC])
in a 50-mL volume. Mixtures were incubated
for $1 hr at room temperature. A 100-mL
volume of indicator cells (A549-ATCC) was
added to each well, and the plates were
placed in a CO2 incubator at 37 C for 6 days.
Wells were scored for the presence or
absence of typical Ad-5 cytopathology. Posi-
tive serum controls were an equine anti–Ad-5
(CDC, Atlanta, Georgia, USA) and a bovine
anti–Ad-5.
Tetracycline biomarker and age determination
First premolars from raccoons and skunks
were shipped to Matson’s Laboratory (Mill-
town, Montana, USA) for TTCC and age
determination. TTCC presence was deter-
mined with ultraviolet light at 1003 magnifi-
cation with a LeitzTM compound microscope
(Leica Microsystems GmbH, Wetzlar, Ger-
many; G. Matson pers. comm.). Ages were
determined through the cementum method
(Johnston et al. 1987). When ages could not be
determined, individuals were assigned as
juvenile or adult based primarily on body size
and tooth characteristics (Grau et al. 1970).
ONRAB detection from oral swabs
An assay was developed for the AdRG1.3
vaccine in ONRAB according to Knowles et al.
(2009a, b). A positive amplicon control (PAC)
was generated using primers that flanked the
assay target region (Ad5E3-F, GCGGACG-
GCTACGACTGAATGTTA; RVG-R, TTGT-
TTGGGCAGCTGAGGTGATGT). The PAC
FIGURE 3. Preselected random live-trapping points and locations of raccoon (Procyon lotor) and striped
skunk (Mephitis mephitis) captures during pre– and post–oral rabies vaccination (ORV) sampling periods in
the Ontario Rabies Vaccine Bait (ONRAB) field trial in West Virginia, USA, 2011. The hatched area
represents the 2011 vaccinia-rabies glycoprotein (V-RG) ORV zone.
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dilution amplification series showed the assay to
be consistently sensitive to a level of detection
of approximating 10 copies of viral DNA.
Oral Swab samples stored in universal viral
transport tubes (Becton Dickinson, Sparks,
Maryland, USA) were shipped for analysis to
the Animal Health Diagnostic Center. Nucleic
acid was purified from 175 mL of the medium
using a MagMax Kit (ABI 1840). The ABI
Path-ID mastermix (ABI, Loughborough, UK)
was used for PCR amplification. Forward and
reverse primers were used at a concentration
of 400 nM and the probe was used at a con-
centration of 120 nM. Purified nucleic acid
(4 mL) was used per reaction in a total volume
of 25 mL. The quantitative (q)PCR reactions
were run on an ABI 7500 thermocycler.
Cycling conditions were 95 C for 10 min,
followed by 40 cycles of 95 C for 15 sec and
60 C for 1 min. In addition to the test samples,
each set of reactions included two or more
negative control wells, a positive extraction
control well with AdRG1.3 vaccine diluted at
131025 in transport medium, a negative ex-
traction control consisting of transport medi-
um only, and a PAC well with a calculated
copy number of 100.
ONRAB vaccine-bait contact
A communications campaign to raise public
awareness of the field trial, ORV and the risks
of bait and vaccine contact, and the need to
report potential vaccine exposures included a
National Environmental Policy Act, Environ-
mental Assessment 30-day public comment
period (August–September 2011); talking
points and a flow chart algorithm (Fig. 4) for
responding to calls and categorizing vaccine
vs. bait contacts (August–September 2011); a
press release (September 2011); and a presen-
tation on the field trial to the Greenbrier
County Commission that included two televi-
sion interviews (September 2011). We provid-
ed ONRAB information and safety guidelines,
the material safety data sheet, and the
ONRAB ground baiting protocol to Wildlife
Services (WS) staff responsible for ground
baiting (September 2011).
Statistical methods
Contingency tables and the Cochran-Man-
tel-Haenszel (CMH; Agresti 1996) test were
used to determine whether the proportions of
individuals pre- and post-ORV differed among
FIGURE 4. Suggested standard operating procedure (SOP) for documenting and managing human
contacts with Ontario Rabies Vaccine Baits (ONRABs) during field trial in West Virginia, USA, 2011. This is a
suggested SOP. State and county health departments were not required to follow this SOP and may have
altered the components to accommodate their program. This document was originally created for vaccinia-
rabies glycoprotein (V-RG) oral rabies vaccination (ORV) distribution by Andrea McCollum and Brett
Petersen in 2010 and modified by Richard Chipman for ONRAB in 2011. The content is based on information
and SOPs from the US Department of Agriculture, Texas Department of State Health Services, and Ohio
Department of Health. CDC Emergency Operations Center phone number: (770) 488-7100.
586 JOURNAL OF WILDLIFE DISEASES, VOL. 50, NO. 3, JULY 2014
sampling cells (1–4). The CMH test was used
to determine whether age, sex, and antibody
status were conditionally independent across
sampling cells. McNemar’s test for dependent
samples was used to determine whether the
proportion of antibody-positive individuals
differed pre- and post-ORV. The CMH test
was used to determine whether relationships
existed between biomarking, serology, age,
and sex. Among post-ORV samples, we ex-
plored differences by multiple logistic regres-
sion. Significance was set at P,0.05. All
statistical analyses were conducted in SAS
2009 (SAS Institute Inc. 2009).
RESULTS
Target species biomarker and rabies serology
Antibody prevalence was 9.6% among
raccoons (n5395) before ONRAB baiting
(Table 1) in the field trial area. Cell-to-cell
proportion of antibody-positive raccoons
during pre-ORV sampling did not differ rel-
ative to sex (CMH51.92, df51, P50.166) or
age (CMH52.51, df51, P50.113). Cell-
to-cell proportion of antibody-positive
demographic classes ranged from 0% to
25% (Table 2). Adults comprised a greater
proportion of individuals than juveniles.
By contrast, 49.2% of raccoons (n5262)
sampled post-ORV were antibody positive
(S5102.68, df51, P,0.001). Cell-to-cell
proportion of antibody-positive demo-
graphic classes ranged from 16% to 89%
(Table 2) and did not differ by sex
(CMH53.75, df51, P50.053) but did by
age (CMH514.99, df51, P50.0001) due
to a lower proportion of antibody-positive
juveniles in cells 1 (x256.28, df51, P5
0.012) and 2 (x257.06, df51, P50.008).
TTCC presence was similar (P50.7303)
at 10% (3/31) among raccoons during
TABLE 1. Prevalence (%) of antibody to rabies virus by species sampled for pre– and post–Ontario Rabies
Vaccine Bait (ONRAB) bait distribution in a field trial in West Virginia, USA, 2011.a
Pre-ONRAB Post-ONRAB
Species % n % n
Raccoon (Procyon lotor) 9.6 395 49.2 262
Striped skunk (Mephitis mephitis) 5 20 7 28
Gray fox (Urocyon cinereoargenteus) 0 1 100 2
Red fox (Vulpes vulpes) — 0 100 1
Coyote (Canis latrans) — 0 100 1
Total 9.4 416 45.9 294
a One skunk and one coyote were collected as roadkill within sampling cells during the post-ONRAB field trial period.
TABLE 2. Rabies virus antibody prevalence (%) in raccoons (Procyon lotor) and corresponding sample size
for pre– and post–Ontario Rabies Vaccine Bait distribution by sex and relative age and sampling cell in a field
trial in West Virginia, USA, 2011.a
Interval Cell
Adult male Adult female Juvenile male Juvenile female
% n % n % n % n
Prebait 1 13 32 7 30 0 21 0 18
2 10 40 15 27 11 19 0 10
3 10 49 13 32 7 14 12 17
4 22 23 4 24 25 12 0 20
Postbait 1 68 25 38 21 39 18 16 19
2 56 9 89 9 31 16 27 7
3 86 21 67 18 64 11 44 9
4 54 26 38 21 32 19 39 13
a Adult ($1 yr old) and juvenile (,1 yr old) raccoons were based on specific ages determined by cementum annuli. Fifty
raccoons for which there were no tooth or usable samples were assigned to juvenile or adult age classes based on size and
tooth characteristics (Grau et al. 1970).
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pre-ORV but was significantly higher (P,
0.0001) at 39.2% (48/122) among antibody-
positive raccoons post-ORV (Table 3). No
relationships were detected pre-ORV be-
tween biomarking and RVNA (P50.5300),
age (P50.1716), or sex (P50.1657). How-
ever, differences were noted post-ORV
relative to age and RVNA (P,0.0001),
but not for sex (P50.6074).
Only 27 raccoons marked during the
pre-ORV period (6.8%) were recaptured
post-ORV (10.3%). One raccoon recap-
ture had detectable RVNA pre- (0.06 IU)
and post-ORV (0.32 IU). This individual
was TTCC negative. Eight of these 27
raccoons had RVNA post-ORV (including
the one previously mentioned), but only
two were biomarker positive. Four of six
raccoons (n525, two were not tested for
biomarker) that were biomarker positive
post-ORV were antibody negative. Two of
23 raccoons with suitable pre-ORV tooth
samples were TTCC positive.
One of 20 skunks had detectable RVNA
pre-ORV; two of 28 had RVNA post-ORV
(Table 1). No skunks were recaptured.
Other species tested for RVNA represented
incidental captures of rabies reservoir
species in North America (Table 1; Blanton
et al. 2011).
There was no evidence of adenovirus
antibodies in 416 animals from the pre-
ORV period. Seven of 296 (2.4%) samples
demonstrated AdRG1.3 VNAs post-ORV:
six raccoons and one skunk. Adenovirus
antibodies were detected in 10 of 23 cattle
serum samples collected within the study
area prior to ONRAB distribution. Fewer
(three of 23) cattle (different individuals
from the pre-ORV sample) had VNA to
adenovirus post-ORV.
ONRAB detection from oral swabs post-ORV
Oral swab samples were collected from
125 target and nontarget individuals live-
trapped from days 1 to 6 post-ORV.
Individual raccoons on days 2, 3, and 4
and a Virginia opossum (Didelphis virgi-
nianus) on day 4 had qPCR values ,35,
which are considered strong positives
(Knowles et al. 2009a). An additional nine
raccoons and four opossums with .35
qPCR values ,40 were captured on days
1–4. No ONRAB was detected on days 5
or 6. Two of 15 raccoons and two of 12
opossums had .35 qPCR values ,40 on
day 1. These are not strong positives, but
they represent the only animals sampled
that could have had vaccine contact during
day 1 after ONRAB distribution. It was
TABLE 3. Rabies virus–neutralizing antibody (RVNA) and tetracycline (TTCC) biomarker results for 341
and 248 raccoons (Procyon lotor) sampled before and after the distribution of Ontario Rabies Vaccine Bait in a
West Virginia, USA, field trial in 2011.a
Interval Antibody status Ageb
TTCC negative TTCC positive
Male Female Male Female
Prebait RVNA negative Adult 114 85 5 5
Juvenile 41 45 11 4
RVNA positive Adult 15 8 1 1
Juvenile 3 2 1 0
Postbait RVNA negative Adult 23 28 2 3
Juvenile 28 26 9 7
RVNA positive Adult 39 30 9 5
Juvenile 3 2 22 12
a Four raccoons from the prebait interval that were RVNA negative and TTCC negative were excluded because sex was
not recorded; one raccoon from the prebait interval that was RVNA positive and TTCC negative was also excluded
because sex was not recorded.
b Specific ages were used when they were available from cementum annuli to assign to adult or juvenile age classes.
Otherwise, raccoons were assigned to juvenile or adult age classes based on size and tooth characteristics (Grau et al.
1970).
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not possible to determine the day of
vaccine contact for the animals deemed
positive from days 2–4.
ONRAB vaccine bait contact
No human or domestic animal bait or
vaccine contacts were reported to the
WVDHHR or WS during this field trial.
DISCUSSION
North American rabies management
goals include elimination of rabies at its
source in wildlife reservoirs (USDA 2008a,
b). Raccoon rabies has not spread appre-
ciably in the USA since ORV intervention
began in the late 1990s, but contingency
actions in the US and point infection
control in Ontario (Rosatte et al. 2001),
Quebec (Mainguy et al. 2012), and New
Brunswick have been integrated into
control to achieve this goal (Slate et al.
2009). Lack of progress toward elimina-
tion of raccoon rabies in the US has been
attributed in part to relatively low popu-
lation immunity with ORV strategies
involving a single annual late summer
aerial baiting with 750-m parallel flight
line spacing at 75 baits/km2 with Raboral
V-RG.
Antibody prevalence of 49.2% among
raccoons (unadjusted for the 9.6% pre-
ORV level) after ONRAB distribution was
the highest WS has observed for a first
baiting at 75 baits/km2 and 750-m flight
line spacing where the RVNA baseline had
been measured. Field trial replication was
recommended and initiated in 2012 to
determine whether raccoon population
immunity becomes asymptotic after a
second successive annual baiting, similar
to the pattern observed for Raboral V-RG,
but at antibody prevalence levels neces-
sary to pursue raccoon rabies elimination
more aggressively. Additionally, replicat-
ing this trial will allow for further inves-
tigation of differences noted in juvenile
antibody prevalence across sampling cells.
Population immunity levels approaching
70% have been cited as a general thresh-
old for rabies elimination–based modeling
(Anderson et al. 1981) and expertise
(Coleman and Dye 1996); however, 60%
(or between 50% and 60%) may be
sufficient to break the rabies transmission
cycle, with higher population immune
responses increasing certainty of success
(Thulke and Eisinger 2008).
Although this field trial was not specif-
ically designed to compare ONRAB and
Raboral V-RG, a mean antibody preva-
lence of 17.069.9% (SD; n511), uncor-
rected for mean RVNA of 4.964.8%
(n513) was observed after a first baiting
with Raboral V-RG in naı¨ve areas under
essentially the same initial ORV baiting
characteristics during 2001–09 in Ala-
bama, Florida, Georgia, Maine, North
Carolina, Pennsylvania, Tennessee, and
Virginia and similar raccoon density indi-
ces (USDA 2011c) as in this field trial,
except in Florida (Tables 4, 5). Although
comparative antibody prevalence samples
were not collected in the adjacent Raboral
V-RG zone in West Virginia post-ORV
during 2011, in the 4 yr prior to this
ONRAB field trial, RVNA prevalence
ranged from 18.5% (n5135; 2008) to
46% (n584; 2007). These represent
RVNA levels for areas that have been
subject to annual ORV campaigns at 75
baits/km2 with Raboral V-RG since 2001.
A RVNA prevalence of 9.6% in the pre-
ORV sample was higher but fell within 1
SD of the mean for areas of similar status
before ORV with Raboral V-RG (Table 4).
Background RVNA is likely related in part
to naturally acquired immunity from
sublethal exposures (Bell et al. 1972;
Botros et al. 1979) to raccoon rabies vi-
rus (Fig. 2) or bat rabies virus variants
enzootic in the study area (Blanton et al.
2011). Although raccoon rabies was enzo-
otic in the West Virginia field trial zone,
previous studies have reported higher
RVNA prevalence in raccoon populations
in areas that were naı¨ve to the raccoon
rabies virus variant and ORV (McLean
1971; Ramey et al. 2008). Movement of
orally vaccinated raccoons across the
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established buffers for this field trial from
the nearby Raboral V-RG ORV zone
(Fig. 3) cannot be completely ruled out
as a potential contributing factor. There
are no known wildlife rehabilitation facil-
ities in the immediate area that could have
released hand-inoculated raccoons as a
source of RVNA pre-ORV.
The significant relationship between
TTCC and RVNA adds confidence that
antibody prevalence was, in large part,
attributable to ONRAB bait consumption
(Johnston and Voight 1982; Rupprecht et
al. 1987; Rosatte et al. 2009b). That TTCC
was not closer to unity than 48 of 122 for
antibody-positive raccoons may be largely
a function of using first premolar teeth for
biomarker detection. Canine teeth and
mandibular bone are superior tissues for
TTCC biomarking (Linhart and Kennelly
TABLE 4. Rabies virus–neutralizing antibody prevalence before and after initial oral rabies vaccination
(ORV) with Raboral V-RG, in areas never previously subjected to ORV. Raccoon population density indices
associated with these regions are shown for post-ORV sampling periods (2001–09).
State (US) Year
Bait density
(baits/km2)a
Prevalence
(%) n Regionb
Raccoon
density indexc
No. of
studies
Alabama 2002 0 3 68 Georgia-Alabama-
Tennessee
— —
2003 75 33 67 Georgia-Alabama-
Tennessee
6.5 2
2002 0 11.3 133 Selma — —
2004 75 13 99 Selma 8.9 2
2005 0 1 84 Birmingham — —
2005 75 2.7 113 Birmingham n/a 0
Florida 2003 0 9 99 Mainland (not
Pinellas County)
— —
2003 75 9 65 Mainland (not
Pinellas County)
17.0 5
Georgia 2003 0 0 19 Georgia-Alabama-
Tennessee
— —
2004 75 30.2 116 Georgia-Alabama-
Tennessee
n/a 0
Maine 2002 0 14 21 Hodgdon — —
2003 0 0 11 Hodgdon — —
2003 70 20 82 Hodgdon 3.6 2
2007 0 1 74 Caribou — —
2009 75 26.4 144 Caribou 12.1 2
North
Carolina
2005 0 3 30 Appalachian Ridge — —
2005 75 7.5 120 Appalachian Ridge n/a 0
Pennsylvania 2002 0 9.9 192 Appalachian Ridge — —
2002 75 13 39 Appalachian Ridge n/a 0
Tennessee 2002 0 3 30 Appalachian Ridge — —
2002 75 11 74 Appalachian Ridge 9 1
Virginia 2001 0 9 33 Appalachian Ridge — —
2002 0 3 29 Appalachian Ridge — —
2002 75 22 68 Appalachian Ridge 4.7 2
Totald 0 54.964.8 841 — —
Totald 70/75 517.069.9 987 — —
a 0 5 sampling conducted in an ORV-naı¨ve area (i.e., has never been baited for ORV).
b Regions represent distinct ORV zones within a given state where sampling was conducted independent of other regions.
c n/a 5 not applicable (no density studies were conducted).
d Means and standard deviations of unbaited (naı¨ve 5 0) vs. baited areas were generated from 13 and 11 events,
respectively (n513, n511).
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1967; Algeo et al. 2013), but we collected
first premolar teeth as a less intrusive
procedure so that raccoons could be
released after full recovery from sedation.
Canine tooth sampling would have re-
quired euthanasia and eliminated the
opportunity to obtain valuable biologic
information in future field trials through
recaptures.
Background sources could have contrib-
uted to the TTCC level of 48 of 122 RVNA-
positive raccoons post-ORV. The most
likely background TTCC sources may have
included consumption of medicated feeds
sometimes used for cattle production and
nonspecific fluorescence that may be found
naturally (Chopra and Roberts 2001).
TTCC was detected in 28 of 341 (8%)
pre-ORV (3/31 antibody-positive raccoons
and 25/310 antibody-negative raccoons
were biomarker positive pre-ORV) and 69
of 248 (28%) of post-ORV raccoons irre-
spective of RVNA status. However, there
was significantly higher biomarker post-
ORV irrespective of antibody status com-
pared with pre-ORV. TTCC exposure
through bait contact only (i.e., the raccoon
failed to puncture the blister pack contain-
ing the vaccine) may account for a portion
of TTCC-positive, antibody-negative rac-
coons post-ORV. Only one of 27 raccoons
recaptured during post-ORV trapping that
also had detectable RVNA pre-ORV had an
elevated titer suggestive of an anamnestic
response to ONRAB consumption, but this
was not supported by TTCC marking.
Sample size was inadequate to evaluate
the immune response of ONRAB in
striped skunks. The four skunk captures
during raccoon density indexing (Table 5)
suggests low population densities. Howev-
er, it may be possible to improve skunk
capture rates in future trials using baits
more attractive to skunks (Rosatte et al.
1992).
There was no evidence of AdRG1.3
VNAs in target species pre-ORV. That
only 2.4% (six raccoons and one skunk) of
target species post-ORV had AdRG1.3
VNAs is likely a function of the virus
vector being adapted to human hosts.
Additional serologic surveys are planned
for the replicate 2012 West Virginia trial to
monitor AdRG1.3 VNA patterns. Howev-
er, the presence of higher levels of
adenovirus VNAs in cattle surveyed pre-
ORV than post-ORV might be due to
cross-reactivity to natural exposure to a
ruminant adenovirus (10 known species in
two genera), as there are no licensed
ruminant adenovirus vaccines.
Absence of reported ONRAB bait con-
tacts in humans was not surprising given
that the 79,027 baits were distributed in
predominantly rural areas. As field trials
expand to include urban-suburban envi-
ronments where contacts would be ex-
pected to increase, contact rates may be
compared with those reported for Raboral
V-RG (CDC 2013). About 120 million
Raboral V-RG baits have been distributed
from 1995 to 2011, with 1,464 human-bait
contacts (i.e., picking up bait, finding bait
in a yard, or removing bait from a pet
dog’s [Canis familiaris] mouth, feces, or
vomit), equating to a human contact rate
TABLE 5. Raccoon (Procyon lotor) population density indices on the basis of 50 cage traps set for 10
consecutive nights and moved to cover a 3-km2 study area within the area that served as the Ontario Rabies
Vaccine Bait field trial study area in West Virginia, USA, 2011.
Year Study name No. of skunks County Density (raccoons/km2) Area habitat class
2006 WVGREENB06 0 Greenbrier 8.2 Rural (mixed forest)
2007 WVGREENB07 2 Greenbrier 12.2 Rural (mixed forest)
2010 WV00310 0 Greenbrier 12.0 Agriculture (pasture/hay)
2010 WV00410 2 Greenbrier 10.7 Rural (mixed forest)
2010 WV00510 0 Monroe 6.6 Rural (mixed forest)
2010 WV00610 0 Monroe 7.0 Rural (mixed forest)
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of 1/68,521 baits distributed (USDA
2011b; Roess et al. 2012), resulting in
only two known adverse reactions (CDC
2009; USDA 2010a).
Between 2006 and 2011, $3.9 million
ONRAB baits with an affixed phone label
were distributed in Ontario with a call rate
of 1/65,140 baits (64 calls) distributed.
Fifteen calls involved possible vaccine
contact (unconfirmed) as a result of
handling a punctured bait or removing a
bait from a dog’s mouth, or a contact rate
of 1/260,560 baits distributed. There were
no reports of adverse events associated
with reported human-bait contacts (On-
tario Ministry of Natural Resources 2007,
2008, 2009, 2010, 2011). Between 2007
and 2009, only 16 reports of human
exposure occurred in Quebec despite the
distribution of almost 2 million baits
(J. Mainguy unpubl. data). In 2010, $1
million ONRAB baits were distributed in
Quebec, with no human bait contacts
reported (Ontario Ministry of Natural
Resources 2011).
From 1995 to 2008, 1,327 pet or other
domestic animal Raboral V-RG bait con-
tacts were documented, equating to a
contact rate of 1/75,596 baits distribut-
ed (USDA 2011b). There were no reports
of adverse reactions among the 261 pets
with bait contacts, except eight dogs
experienced vomiting or diarrhea after in-
gesting several baits. Animals that contact
Raboral V-RG or ONRAB vaccine will
most likely be immunized against rabies or
receive a boost from a previous rabies
vaccination.
Using a liberal interpretation of oral
swab analysis, 17 (12 raccoons and five
opossums) of 125 samples (14%) were
positive for AdRG1.3 the first 4 days after
ONRAB distribution. No AdRG1.3 was
detected in wild-captured animals within
the ONRAB field trial zone on days 5 or 6.
Knowles et al. (2009b) reported excretion
of the vaccine in the oral cavity at 0.8% of
oral swabs and 6.8% of fecal specimens
from experimental animals subjected to
oral instillation. One skunk shed a small
amount of virus in feces on day 14.
Although fecal swab analysis was not
conducted in this field trial, it will be
considered in future ONRAB field trials.
However, AdRG1.3 has been observed to
remain stable through serial passage of
infected lung tissue in the cotton rat
(Sigmodon sp.), one of the few species
susceptible to human adenovirus infection
(Knowles et al. 2009a).
Knowles et al. (2009b) reported no
adverse histologic effects for AdRG1.3
PCR-Southern Blot positives (18/1,280;
1.4%) and negative tissue samples ob-
tained from experimental vaccinates or
contact animals. Likewise, no histopatho-
logic lesions were observed in a compan-
ion captive study for this field trial in the
Virginia opossum, eastern cottontail rabbit
(Sylvilagus floridanus), turkey (Meleagris
gallopavo), eastern fox squirrel (Sciurus
niger), and wood rat (Neotoma sp.) that
received a 103 dose of AdRG1.3 per os
(Fry et al. 2013). Although these animal
safety findings support continuation of
field trials, samples (pre-ORV, n5290;
post-ORV, n5300) from wild-caught tar-
get and nontarget species collected from
the study area will be analyzed and
reported separately to expand the ONRAB
animal safety database.
Results from this field trial led to a
recommendation to initiate a safety and
immunogenicity trial in Ohio in 2012 to
evaluate ground baiting at 150 baits/km2 in
urban-suburban environments where
ORV with Raboral V-RG has occurred
since 2004 at high bait densities, often
twice annually. A field trial was also
initiated in northern Vermont and New
Hampshire and northeastern New York
along the Quebec border in 2012. Site
selection was based on the absence of
raccoon rabies in Quebec since May 2009,
with extensive enhanced surveillance and
ONRAB ORV central to their elimination
strategy.
Given the long-term goal of raccoon
rabies elimination, the absence of cases is
the ultimate measure of success. However,
592 JOURNAL OF WILDLIFE DISEASES, VOL. 50, NO. 3, JULY 2014
indices of bait consumption from bio-
marker and population immunity from
RVNA represent key metrics of ORV
performance for achieving success. Based
on those indices in this first ONRAB field
trial, positive results from comparative
border studies between Raboral V-RG
and ONRAB (Fehlner-Gardiner et al.
2012; Mainguy et al. 2013), and raccoon
rabies control successes in Canada, suc-
cessive year field trials with ONRAB
should reveal whether immune levels
necessary to eliminate raccoon rabies are
attainable, recognizing that ORV strate-
gies will need to be adapted to specific
environments.
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